Form 8-K - Current report:
SEC Accession No. 0000950170-25-106924
Filing Date
2025-08-12
Accepted
2025-08-12 07:40:38
Documents
11
Period of Report
2025-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mreo-20250812.htm   iXBRL 8-K 54014
2 EX-99.1 mreo-ex99_1.htm EX-99.1 281849
  Complete submission text file 0000950170-25-106924.txt   508281

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20250812.xsd EX-101.SCH 58314
14 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20250812_htm.xml XML 6519
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON United Kingdom W1G 0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON United Kingdom W1G 0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38452 | Film No.: 251204052
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)